Aripiprazole and Haloperidol: Beneficial Combination Antipsychotic Therapy for a Schizophrenic PatientKuo, Joseph MD*; Hwu, Hai-Gwo MD†Clinical Neuropharmacology: May-June 2008 - Volume 31 - Issue 3 - p 173-175 doi: 10.1097/WNF.0b013e318123ee01 Case Reports Buy Abstract Author InformationAuthors Article MetricsMetrics Objective: Schizophrenia is a chronic disease that is treated with dopamine antagonists. These drugs can produce intolerable side effects through their blockade of central nervous system dopamine receptors unrelated to schizophrenia. The atypical antipsychotic aripiprazole, a dopamine receptor partial agonist, has mixed agonist-antagonist effects. Its partial agonism is said to protect the patient from the side effects caused by full antagonists at the same time that its antagonism treats the schizophrenia effectively. Case: We report a case in which a low dose of the full antagonist haloperidol, added to aripiprazole, improved antipsychotic efficacy in a 41-year-old man diagnosed with undifferentiated schizophrenia. Result: A 15-mg/d aripiprazole/7.5-mg/d haloperidol regime in this patient improved all previous psychotic symptoms and caused no adverse side effects. The patient's final prolactin concentration using this combination was normal. Conclusion: Further studies are warranted to confirm this observation and to determine the mechanism through which a carefully titrated combination of a full antagonist with a partial agonist can cause such improvement. *Department of Psychiatry, Lotung St. Mary's Hospital, Ilan; and †Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan. Address correspondence and reprint requests to Joseph Kuo, MD, Lotung St. Mary's Hospital, 160 Chong-Cheng South Road, Lotung, Ilan 265, Taiwan; E-mail: firstname.lastname@example.org © 2008 Lippincott Williams & Wilkins, Inc.